UnknownNot Applicable

Analgesic Efficacy of Rhomboid Intercostal Nerve Block for Minimal Invasive Heart Surgery

Turkey (Türkiye)78 participantsStarted 2023-06-01

Plain-language summary

The goal of this clinical trial is to test the analgesic efficacy of rhomboid intercostal nerve block (RINB) in patients undergoing minimal invasive heart surgery (MIHS). The main questions it aims to answer are: * How will the total perioperative opioid consumption of the patients receiving RINB change? * How will RINB effect the patients' numeric rating scores for pain in the postoperative 24-hour period? * How will RINB effect the postoperative extubation times? * How will RINB effect the length of intensive care unit (ICU) stays on the postoperative period? * How will RINB effect the incidence of opioid related side effects? Participants will be divided in two groups: * Block group will receive a RINB before the surgery. * Control group will not receive any nerve block. Researchers will compare the results between the groups to see the postoperative effects concerning opioid consumption as well as the pain scores, respiratory parameters and ICU length of stay of the patients receiving RINB for minimal invasive heart surgery. The hypothesis of this study is that participants receiving RINB for MIHS will have a less total opioid consumption 24 hours postoperatively.

Who can participate

Age range

18 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients between the age of 18-80 undergoing minimal invasive heart surgery Exclusion Criteria: * Allergy to local anaesthetics * Chronic opioid use history * Patients with psychiatric disorders * Patients who are not open to communication * Patients with chronic organ failure * Patients that do not give consent * Patients that need emergency surgery within the first 24 hours of the initial surgery

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Total opioid consumption

Timeframe: 24 hours post-surgery

Trial details

NCT IDNCT05861804

SponsorKoç University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-30

Contact for this trial

Kamil Darçın, MD

+90 505 589 50 99 kdarcin@ku.edu.tr

View on ClinicalTrials.gov More Minimal Invasive Heart Surgery trials